Sibu Kuruvilla, MSE

Name: Sibu Kuruvilla Uniqname: skuruvi Department: MSE   Photo: Joseph Xu, Michigan Engineering, Communications & Marketing

I am a PhD student in Materials Science and Engineering finishing up in February 2017, and am co-advised by Dr. Greve and Dr. Mohamed ElSayed (BME). My research focuses on the development of a nanoparticle-based drug delivery system for hepatic cancer therapy. By using specific antigen targeting on hepatic cancer tissue combined with enzyme-mediated release of a loaded drug, we are showing that we can improve the therapeutic efficacy of conventional chemotherapeutics (e.g. doxorubicin) while reducing their systemic toxicities both in vitro and in vivo.


Nanoparticle design for targeted, enzyme-activated drug delivery to hepatic cancer tissue.


  1. S. P. Kuruvilla, G. Tiruchinapally, M. ElSayed, J. M. Greve. “Valency of N-Acetylgalactosamine ligands on PAMAM dendrimers affects targeting efficacy to the asialoglycoprotein receptor of hepatic cancer cells.” Manuscript in preparation.
  2. S. P. Kuruvilla, G. Tiruchinapally, A. C. Crouch, M. ElSayed, J. M. Greve. “Nanoparticle-doxorubicin conjugates exhibit anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.” Cancer Research. Submitted.
  3. S. P. Kuruvilla, G. Tiruchinapally, M. ElAzzouny, M. ElSayed. “N-Acetylgalactosamine-targeted delivery of dendrimer-doxorubicin conjugates influences doxorubicin cytotoxicity and metabolic profile in hepatic cancer cells.” Advanced Healthcare Materials. In press.
  4. S. H. Medina, G. Tiruchinapally, M.V. Chevliakov, Y.Y. Durmaz, S.P. Kuruvilla, M. ElSayed. “Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells.” Biomaterials 2013, 34, 4655-4666.